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Quantification of residual disease by real-time poly-
merase chain reaction (PCR) will become a pivotal
tool in the development of patient-directed therapy.
In recent years, various protocols to quantify mini-
mal residual disease in leukemia or lymphoma pa-
tients have been developed. These assays assume that
PCR efficiencies are equal for all samples. Determin-
ing t(14;18) and albumin reaction efficiencies for six-
teen follicular lymphoma patient samples revealed
higher efficiencies for blood samples than for lymph
node samples in general. However, within one sam-
ple both reactions had equivalent efficiencies. Differ-
ences in amplification efficiencies between patient
samples (low efficiencies) and the calibrator in quan-
titative analyses result in the underestimation of re-
sidual disease in patient samples whereby the weak-
est positive patient samples are at highest error.
Based on these findings for patient samples, the effi-
ciency compensation control was developed. This
control includes two reference reactions in a multi-
plex setting, specific for the b-actin and albumin
housekeeping genes that are present in a constant
ratio within DNA templates. The difference in thresh-
old cycle values for both reference reactions, ie, the
DCt2 value, is dependent on the amplification effi-
ciency, and is used to compensate for efficiency dif-
ferences between patient samples and the calibrator.
The b-actin reference reaction is also used to normal-
ize for DNA input. Furthermore, the efficiency com-
pensation control facilitates identification of patient
samples that are so contaminated with PCR inhibitory
compounds that different amplification reactions are
affected to a different extent. Accurate quantitation of
residual disease in these samples is therefore impos-
sible with the current quantitative real-time PCR pro-
tocols. Identification and exclusion of these inade-
quate samples will be of utmost importance in
quantitative retrospective studies, but even more so,
in future molecular diagnostic analyses. (J Mol Diag
2001, 3:55–61)
Disease-associated chromosomal markers facilitate spe-
cific detection of malignant cells in patient tissues and
fluids, and have proved useful for diagnostic and prog-
nostic purposes. By means of the polymerase chain re-
action (PCR), malignant cells can be detected to a sen-
sitivity limit of about a single malignant cell in a
background of 105 to 106 normal cells.1 Monitoring the
number of residual malignant cells during the course of
disease may predict for early relapse, preceding appar-
ent clinical manifestation, and may verify the efficacy of
treatment regimens.2–4 Monitoring by quantitative PCR
(QPCR) may become a fundamental tool to support pa-
tient directed treatment in future, at least for certain types
of malignancies. Various QPCR analyses based on com-
petitive PCR strategies have been developed in the
past.5–8 However, the use of these assays is frequently
hampered by a high risk for contamination and the labor-
intensiveness of the technique. Real-time PCR9,10 based
on Taqman chemistry11,12 has innovated PCR technol-
ogy, allowing faster analysis of patient samples in a
closed system, thereby lowering the risk of contamina-
tion. The use of an internal fluorescent probe warrants the
specificity of the reaction and allows for the determination
of sample positivity within the exponential phase of the
reaction.
Various quantitative real-time PCR and RT-PCR proto-
cols have recently been developed for the detection of
disease associated chromosomal translocations,13–16 or
disease-associated T cell receptor or Ig gene rearrange-
ments.17,18 All protocols developed thus far are based on
the assumption that patient samples and calibration sam-
ples have equal efficiencies during amplification. At least
for the amplification of genomic DNA templates this as-
sumption may not be true, since many patient samples
seem contaminated with PCR inhibiting compounds. It is
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exactly for this reason that competitive PCRs have been
developed in the past.5–8 Factors like DNA fragmenta-
tion,19 residual RNA in DNA preparations,20 the presence
of PCR inhibiting compounds like residual anti-coagulant
heparin21 or proteinase K-digested heme compounds
like hemoglobin22 or myoglobin23 will negatively affect
PCR efficiency.
In this report, we demonstrate that the amplification
efficiency for different DNA templates isolated from whole
blood or bone marrow samples is subject to extensive
variation, leading to underestimation of minimal residual
disease or false negative result in quantitative PCR anal-
yses. We developed a general real-time PCR control, ie,
the efficiency compensation control (ECC), to compen-
sate for different efficiencies between patient samples.
This approach comprises the inclusion of two different
reference reactions, one of which is carried out with
mutant primers. Both reference reactions have been de-
veloped to amplify with equivalent efficiencies on the
same template. The exact difference in the threshold
cycle values (Ct) between both reference reactions (DCt
value) is dependent on the amplification efficiencies. This
DCt value can, therefore, be used to calculate the exact
efficiencies of both reactions for each sample in compar-
ison to a calibrator sample, thus providing a way to
compensate for differences in efficiencies between pa-
tient samples and the calibrator in quantitative analyses.
In this way, accurate estimation of residual disease in
patient samples becomes possible, regardless of DNA
quality or the presence of PCR-inhibiting compounds.
Materials and Methods
Real-Time PCR
During PCR amplification, the number of molecules that is
synthesized (Xn) depends on the number of template
molecules present at the beginning of the reaction (X0),
the reaction efficiency (E) and the number of amplifica-
tion cycles (n) (Eq. 1).24 In real-time PCR, sample posi-
tivity is defined as the cycle number at which emitted
fluorescence exceeds the 10 times SD of baseline emis-
sions, and is called the threshold cycle (Ct). The number
of molecules synthesized at the threshold cycle (XCt) is
specific but constant (C) for each type of reaction and
may depend on reporter dye (6-carboxy-fluorescein
(FAM) or 27-dimethyl-4,5-dichloro-6-carboxy-fluorescein
(JOE)).
Xn 5 X0p(11E )nN XCt 5 X0p(11E )CtN X05Cp(11E )2Ct
(1)
Normalization
To correct for differences in DNA or RNA load between
patient samples, the target PCR, t(14;18) in this report, is
normalized to a reference PCR, b-actin in this report, that
is specific for an endogenous housekeeping gene. The
t(14;18) and the b-actin reactions outlined in this report
have equivalent amplification efficiencies, allowing direct
normalization of the t(14;18) PCR to the b-actin PCR at
the Ct level (Eq. 2; K Livak, personal communication and
Applied Biosystems User Bulletin #2).
X0,t arg et
X0, ref
5 X0N 5
C1p(11E )2Ct[t arg et]
C2p(11E )2Ct[ref]
N
when Et arg et 5 Ereff X0N 5 C3p(11E )2DCt1 (2)
PCR Efficiency
The efficiency (E) of a reaction can be determined by a
standard curve. Ct values for serial template dilutions in
dH2O are related to the logarithm of the dilution factor,
and the slope is a measure for reaction efficiency (Eq. 3;
K Livak, personal communication and Applied Biosys-
tems User Bulletin #2):
eff 5 E 5 10 2S 1slopeD 2 1 (3)
Quantification Using a Single Calibrator
For quantification, patient samples can be related to a
single calibration sample, facilitating the use of Eq. 4 (ie,
the comparative Ct method; K Livak, personal communi-
cation and Applied Biosystems User Bulletin #2). How-
ever, this method demands equivalent amplification effi-
ciencies between patient samples and the calibrator.
X0N, sample
X0N, Cal
5
C3p(11ESample)2DCt1S
C3p(11ECal)2DCt1C
N
when ESample 5 ECalf X0N, Sample 5 X0N,Calp~1 1 E)2DDCt1
(4)
whereby DDCt1 5 DCt1S 2 DCt1C
The calibrator (X0N,Cal) used for the quantitation of circu-
lating lymphoma cells during the course of disease in
follicular non-Hodgkin’s lymphoma (NHL) patients is a
100-fold dilution of t(14;18) positive cell line SUDHL6
DNA into a DNA pool obtained from four EBV-induced
lymphoblastoid B cell lines, and equals 750 t(14;18)-
carrying lymphoma cells per 0.5 mg of DNA (equivalent to
75,000 cells).4,14
The Efficiency Compensation Control (ECC)
The ECC outlined in this report is used to compensate for
varying PCR efficiencies between patient samples and
the calibrator. The ECC depends on two different refer-
ence reactions, ie, the multicopy b-actin gene and the
single copy albumin gene. Both reactions amplify with
equivalent efficiencies on identical DNA templates (see
results), but provide different Ct values. The difference
between both Ct values, ie, the DCt2 value, is solely
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dependent on the actual PCR efficiency for that template
(Eq. 5):
X0[bact]
X0[Alb]
5
C4p(11E)2Ct[bact]
C5p(11E)2Ct[Alb]
5 C6p(11E )2DCt2 (5)
whereby DCt2 5 Ct(bact)2Ct(Alb)
DCt2 values can be used to determine amplification
efficiencies for patients samples relative to the efficiency
of the calibrator, providing a correction factor for different
efficiencies between patient samples and the calibrator
(Eq 6):
X0@bact#
X0@Alb]
(sample 5
X0@bact]
X0[Alb]
(Cal )f
C6p(11ESample2DCt2S 5 C6p(11ECal2DCt2Cf
~1 1 ESample! 5 ~1 1 ECal!
DCt2C
DCt2S,
when ESample 5 ECalf DCt2S5DCt2C (6)
This correction factor can be introduced into Eq. 4, facil-
itating the quantification of patient samples relative to a
single calibrator with compensation for different efficien-
cies between patient samples and the calibrator sample
(Eq 7):
X0N,Sample 5 X0N,calp~1 1 ECal! 2H
DCt2C
DCt2SpDDCt1J (7)
DNA Isolation
Patient whole blood sample DNA was isolated by a stan-
dard high-salt lysis method as described by Miller et al.25
t(14;18) PCR Analysis
Amplification reactions are performed in the ABI/Prism
7700 sequence detector (Applied Biosystems, Foster
City, CA). Five hundred nanograms of patient sample
DNA is amplified in duplicate in the presence of 300
nmol/L oligonucleotides MBR-2 (59-TCC CTT TGA CCT
TGT TTC TTG A-39; bp 2816–3037 of GenEMBL data-
base entry acc. 14745) and JH-con,1 160 nmol/L of dual-
labeled fluorogenic MBR internal probe 59-(FAM)-CAC
AGA CCC ACC CAG AGC CC-(TAMRA)-p39, 250 mmol/L
dNTPs, 1.25 U of AmpliTaq DNA polymerase and 4
mmol/L MgCl2 in Sample Buffer A (Applied Biosystems)
in a volume of 50 ml. Samples are heated for 10 minutes
at 95°C and amplified for 50 cycles of 15 seconds at 95°C
and 60 seconds at 60°C.
The Efficiency Compensation Control
Five hundred nanograms of patient sample DNA is am-
plified in duplicate in the presence of 100 nmol/L b-actin
forward and reverse primers,7 100 nmol/L of dual-labeled
fluorigenic b-actin probe,7 300 nmol/L mutant albumin
forward (59-TGA AAC ATA CGT TCC CAA AGA GCC
T-39) and reverse (59-GAG AGG AAG AGT CTT TCA CAC
GTA GA-39) primers, 100 nmol/L of dual-labeled fluori-
genic albumin probe (59-(JOE)-TGC TGA AAC ATT CAC
CTT CCA TGC AGA-(TAMRA)239), 250 mmol/L dNTPs,
1.25 U of AmpliTaq DNA polymerase, and 4 mmol/L
MgCl2 in Sample Buffer A in a total volume of 50 ml.
Amplification conditions are the same as mentioned
above.
Results
To study variation in amplification efficiencies among
patient DNA samples, the efficiencies of our t(14;18) and
albumin PCRs were first tested on cell line DNA. Genomic
DNA from the t(14;18)-carrying cell line SUDHL6 was
serially diluted in dH20 and amplified in duplicate to
construct t(14;18) and albumin standard curves for eight
to ten independent experiments. R2 values of all curves
exceeded 0.98, and reaction efficiencies were calculated
from the slopes (Eq. 3). The average efficiencies for the
t(14;18) reaction (n 5 11) and the albumin reaction (n 5
8) were E 5 0.91 6 0.05 and E 5 0.93 6 0.04, respec-
tively (Table 2). We then determined the efficiencies for
both reactions on patient DNA samples that were isolated
from lymph node biopsies or whole blood specimen (Ta-
ble 2). Lymph node DNA samples most likely seem to
contain higher contents of PCR inhibiting compounds
resulting in lower amplification efficiencies compared to
patient whole blood DNA samples. Both reaction efficien-
cies for each DNA sample compared, showed that a low
efficiency for one reaction was accompanied by a low
efficiency for the other reaction. For lymph node DNA
samples the average efficiencies for the t(14;18) and
albumin reactions are E 5 0.66 and E 5 0.72 respec-
tively, but are E 5 0.94 and E 5 0.94, respectively, for
whole blood DNA samples. The average efficiency differ-
ence (DE value) between both reactions is DE 5 0.023 for
lymph node DNA samples (n 5 3 pairs) and DE 5 20.009
for whole blood DNA samples (n 5 8 pairs).
Based on these observed differences in reaction effi-
ciencies between patient samples (Table 2), we have
developed the “efficiency compensation control (ECC)”.
This control uses two reference reactions that are specific
for the b-actin and the albumin housekeeping genes.
When testing both reaction efficiencies on serial B cell
line DNA pool dilutions (DNA pool from four EBV-induced
B cell lines), both reactions performed with efficiencies of
E 5 0.95 and E 5 0.94 for the b-actin and albumin
reaction, respectively. b-actin is a multicopy gene with
Table 1. Definition of Symbols
Xn number of molecules at cycle n
X0 initial number of molecules
E efficiency of amplification
n number of cycles
Ct threshold cycle
C (C1–C6) constant
XCt number of molecules at Ct
X0N normalization of target molecules
to reference molecules
DCt1 5Cttarget 2 Ctreference
DDCt1 5DCt1sample 2 DCt1calibrator
DCt2 5Ctbact 2 CtAlb
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several pseudogenes and albumin is a single copy gene,
and are present in a constant ratio for genomic DNA
templates. Both PCRs will therefore produce different Ct
values at identical template concentrations (Figure 1). For
genomic DNA templates, the DCt value between these
reactions (DCt2 value) is exclusively determined by the
actual amplification efficiencies for both reactions (Figure
1), and is independent of initial DNA concentration. In the
experiment as described above, the DCt2 value between
the b-actin reaction and the albumin reaction remained
constant over all serial B cell line DNA pool dilutions (500
ng - 8 ng) and was DCt2 5 3.86 6 0.08. Samples that
amplify with high reaction efficiencies will provide lower
DCt2 values in comparison to samples that are contami-
nated with PCR inhibiting compounds and consequently
amplify with lower reaction efficiencies (Figure 1). This
DCt2 value can therefore be used to compensate for
efficiency differences between patient samples and the
calibrator in quantitative minimal residual disease stud-
ies. The target and reference PCRs should be performed
on the same template dilution to exclude differences in
reaction efficiencies.
We then calculated the DCt2 value that is theoretically
needed between two reference PCRs to distinguish be-
tween efficiency differences as low as E 5 0.05. This will
of course depend on the reproducibility of both Ct values
for the reference reactions. The standard deviations in Ct
values for both reference reactions performed on the
serial B cell line DNA pool dilutions as described above
ranged between 0.007 cycles for 0.5 mg DNA to 0.11
cycles for the highest dilution (0.8 ng DNA). Assuming a
SD in Ct values of 0.11 cycles for both reference reac-
tions, the DCt2 value between both reactions needs to be
in the order of ten cycles to distinguish between effi-
ciency differences among DNA samples as low as DE 5
0.05. No combinations of multicopy gene PCRs (b-actin,
18S ribosomal DNA) versus single copy gene PCRs (al-
bumin, RNase-P) were identified that produced a suffi-
cient DCt2 value. As an alternative, a mutant albumin
primer pair was designed that amplified with an efficiency
of E 5 0.96, compared to the b-actin PCR (E 5 0.95 as
described above). The mutant albumin primer pair pro-
duced Ct values that were about 6 cycles higher Ct
values for each template dilution in comparison to the
wild-type albumin reaction. The DCt2 values between the
b-actin PCR and this mutant albumin PCR was about 9
cycles over all template dilutions tested. This PCR com-
Table 2. t(14;18) and Albumin PCR Efficiencies for Follicular NHL Patient Lymph Node and Peripheral Blood DNA Samples
Patient
no.
Patient
biopsy
t(14;18) PCR product
length (bp)† Et(14;18) EAlbumin DE
SUDHL6 385 0.91 6 0.05 0.93 6 0.04 20.02
(n 5 11) (n 5 8)
1 LN 312 0.75a 0.70e 0.05
2 LN 363 0.74a 0.72e 0.02
3 LN 350 0.59a 0.59e 0
4 LN 360* 0.67b/0.59a ND —
5 LN 267* 0.63b/0.58a ND —
6 LN 299 ND 0.95e —
7 LN 449 ND 0.65e —
Mean 343 0.66 0.72 0.023
8 PB 398 0.97c 0.95f/0.91h 0.04
9 PB 367 1.03c 0.97f 0.06
10 PB 366 0.89c 1.0f/0.94h 20.08
11 PB 329 0.84c 0.85f 20.01
12 PB 313 1.05d 0.96g 0.09
13 PB 343 0.91d 0.99g 20.08
14 PB 520 0.91d 0.92g 20.01
15 PB 337 0.89d 0.97g 20.08
16 PB 336* ND 0.87g —
Mean 368 0.94 0.94 20.009
LN, lymph node; PB, peripheral blood.
*Larger PCR products are also formed due to priming of JHcon primer to downstream JH-gene segments.
†Product size was determined from the breakpoint sequence and confirmed by gel-electrophoresis.
a–hSamples amplified within the same amplification reaction.
Figure 1. Theoretical schematic illustration of b-actin and albumin amplifi-
cation curves at high and low reaction efficiencies (E). The b-actin (black
curves) and albumin (gray curves) amplification curves and Ct values at
high (solid lines) and low (stippled lines) reaction efficiencies for a
hypothetical genomic DNA template concentration. Low reaction efficiencies
result in higher Ct values for both reaction in a non-linear relationship (Eq.
1). DNA templates with higher efficiencies for both reactions will have lower
difference in Ct values between both reference reactions (low DCt values)
than templates with lower reaction efficiencies (high DCt values).
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bination may work for the Efficiency Compensation Con-
trol. To minimize variation in Ct values for both reactions,
a multiplex PCR was developed. Using 100 nmol/L of
b-actin primers and 300 nmol/L of mutant albumin prim-
ers, both reactions produced Ct values of 19.98 6 0.10
and 30.06 6 0.03, respectively, in a multiplex setting, and
Ct 5 19.25 6 0.01 and 27.62 6 0.04, respectively, in
separate PCRs.
The ECC was tested in a retrospective study on 47
selected blood and bone marrow DNA samples obtained
from 12 follicular NHL patients that had been isolated
between 1990–1994 using the high-salt-lysis method.25
Two of these samples had previously demonstrated se-
vere PCR inhibition as assessed by conventional PCR
(not shown). PCR inhibition was not due to DNA degra-
dation as determined by gel electrophoresis (not shown).
When performing the ECC multiplex PCR, thirty-two sam-
ples produced reasonable Ct values for both reference
PCRs with DCt2 values (range DCt2 5 8.19–9.88; mean
DCt2 5 9.04). Assuming an average amplification effi-
ciency of E 5 0.94 for these samples (Table 2), the
efficiency for each sample was then calculated based on
the DCt2 value and ranged between E 5 0.83 and E 5
1.07 (equation 6). Fifteen remaining patient samples
(32%) produced DCt2 values lower than DCt2 5 8.19
(DCt2 5 26.83 to DCt2 5 7.82), and theoretically corre-
spond to abnormal efficiencies of E 5 1.15 and higher.
These samples may suffer from severe PCR inhibition that
affects both reference PCRs to a different extent, and can
therefore not be corrected for different efficiencies using
the ECC. Analysis of DCt2 values from freshly isolated
patient DNA samples in a prospective study revealed that
2 out of 50 samples (4%) suffered from this same prob-
lem (not shown).
The DCt2-based efficiencies were compared to effi-
ciencies that were calculated from standard curves. Four
samples with high DCt2 values (low efficiency) and four
with low DCt2 values (high efficiency) were selected to
construct standard curves. For seven out of eight sam-
ples, the ECC determined efficiencies match the efficien-
cies as determined from the standard curves of the t(14;
18) and albumin PCR (Table 3). For five samples, the
ECC based efficiencies fall within the SD of the efficien-
cies that were derived from standard curves.
Discussion
In quantitative PCR studies monitoring for minimal resid-
ual disease, patient samples are compared to a golden
standard that either consists of a well-defined calibrator
sample (ie, the comparative Ct method) or consists of a
calibrator serial dilution. All real-time quantitative PCR
studies performed thus far are based on the assumption
that PCR efficiencies are the same for patient samples
and the calibrator. However, many factors affect PCR
efficiency and consequently the outcome of quantitative
PCR analyses. It is commonly believed that amplicon size
plays an important role in this matter, as well as contam-
inating factors in the patient sample that will inhibit the
amplification reaction and will therefore delay reaction
efficiency. A few of these PCR inhibiting factors have been
characterized that interfere with quantitative PCR analyses,
especially within the hemato-oncology field.19–23
Testing the efficiencies for the t(14;18) target and al-
bumin reference PCR for various patient DNA samples,
efficiencies for both reactions varied between different
patient samples probably due to contaminating PCR in-
hibiting compounds. PCR efficiency was not affected by
amplicon size (Table 2), at least for amplicons ranging
between 89 and 520 bp, nor was it due to DNA degra-
dation. DNA templates isolated from patient lymph node
biopsies amplify with lower efficiencies in comparison to
patient whole blood DNA samples (Table 2). Most impor-
tantly, for each DNA sample the efficiencies for both
PCRs were equivalent, indicating that a low t(14;18) re-
action efficiency for a DNA template is accompanied by
a similar low efficiency for the albumin reaction for that
same template. This indicates that PCR inhibiting factors
affect different reactions performed on the same template
to a similar extent. For all t(14;18) and albumin standard
curves, the deviations of Ct values for all template dilu-
tions relative to the regression curve were equivalent, and
no evidence was found for increasing deviations at
higher template dilutions as should be expected in case
of dilutable PCR inhibition (all r2 values exceeded 0.98
but in general were in the order of 0.995). PCR inhibition
for the samples evaluated in this study was non-dilutable,
and is presumably caused by compounds that tightly bind
to the DNA like hemoglobin degradation compounds.
Our results show that quantitative studies tend to suffer
from efficiency differences between samples, leading to
inaccurate results. For instance, lower reaction efficien-
cies for patient samples resulting in higher Ct values will
lead to underestimation of residual disease content. This
especially affects patient samples with low residual ma-
lignant cell numbers. Normalization of the target PCR (the
t(14;18) reaction in this report) to a reference PCR, usu-
ally specific for an endogenous housekeeping gene, will
only partially compensate for this problem since the num-
ber of reference gene copies is always relatively high in
comparison to the number of target copies reflecting the
amount of malignant cells. The efficiency compensation
control (ECC) was developed to compensate for sample
specific efficiency variation in comparison to a calibrator
(equation 7), and consists of a multiplex PCR for two
endogenous house keeping genes, ie, b-actin and albu-
Table 3. Comparison of Reaction Efficiency as Determined
from the Efficiency Compensation Control (EECC)
and as Determined from the Slope of Standard
Curves (ESC)
Patient no. DCt2 EECC ESC
17* 9.88 0.83 0.92 6 0.01
17† 9.47 0.88 0.84 6 0.05
18* 9.41 0.89 0.89 6 0.01
19* 9.47 0.88 0.92 6 0.01
1* 8.32 1.05 1.04 6 0.02
4* 8.51 1.02 1.0 6 0.05
20* 8.66 1.0 1.06 6 0.08
21* 8.56 1.01 0.96 6 0.04
Patient sample DNA isolated from peripheral blood samples* or
bone marrow aspirates.† The experimentally determined efficiency
(ESC) is the average efficiency for the b-actin and the mutant albumin
reaction as calculated from the slope of the standard curves.
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min, that are present in a constant ratio in DNA templates
but that produce different Ct values (DCt2) for identical
template. Both reactions performed with equivalent effi-
ciencies on serial template dilutions, and it is reasonable
to assume that both ECC reference reactions will be
equally affected by contaminating PCR inhibiting sub-
stances as is the case for the t(14;18) and wild-type
albumin PCR. The DCt2 value is therefore independent of
initial template concentration, but depends on the exact
amplification efficiencies (equation 6). The ECC can the-
oretically distinguish between patient samples that differ
in amplification efficiencies as low as E 5 0.05. Disease
associated chromosomal aneuploidy involving the b-ac-
tin or albumin genes may affect results obtained by the
ECC. This is unlikely for follicular NHL blood or bone
marrow samples since the total number of circulating
t(14;18) positive lymphoma cells during the course of
disease is in general below five percent of total mononu-
clear cells.3,4,8 However, for leukemias with a high tumor
cell percentage in blood and bone marrow samples dur-
ing apparent disease in contrast to clinical remission
phases, this could be a problem.
Patient DNA templates that had been stored for several
years produced abnormal ECC DCt2 values for 32% of
the samples compared to 4% of freshly isolated patient
DNA samples. For these samples, the ECC will not be
useful to correct for efficiency differences in comparison
to a calibrator sample. These samples probably contain
so many PCR inhibiting compounds that different PCRs
are affected to a different extent. Quantitation of residual
disease in these samples will therefore not be possible.
The ECC seems very useful in identifying such patient
samples in quantitative analyses.
In conclusion, the ECC serves three purposes: first, the
b-actin Ct value for each sample is used to normalize for
different DNA input. Second, the ECC DCt2 value is used
to compensate for efficiency difference in comparison to
the calibrator. Third, the ECC identifies patient DNA tem-
plates that may not be quantifiable for minimal residual
disease content due to unequal inhibition of the various
amplification reactions. Since the ECC uses two refer-
ence PCRs that are specific for endogenous house keep-
ing genes, it may be applicable as a general control in
real-time quantitative studies using genomic DNA tem-
plates. In our opinion, the ECC approach is a powerful
control for TAQMAN-based analyses that can be per-
formed in the ABI PRISM 7700 system (Applied Biosys-
tems) but needs further evaluation in other real-time PCR
systems. For probe designs, other fluorescent reporter
groups can be used, but FAM in combination with JOE or
VIC proved to be a useful combination in a multiplex
setting. Hydrolyzing probes may be replaced by molec-
ular beacons or scorpion primers.26
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